Vascular Biogenics Ltd. (VBLT) Shares Down 2.8%
Vascular Biogenics Ltd. (NASDAQ:VBLT) shares traded down 2.8% on Monday . The company traded as low as $4.12 and last traded at $4.14, with a volume of 121,924 shares changing hands. The stock had previously closed at $4.26.
A number of research analysts have weighed in on the stock. Zacks Investment Research raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Thursday, July 14th. HC Wainwright assumed coverage on shares of Vascular Biogenics in a report on Tuesday, June 28th. They issued a “buy” rating and a $11.00 price objective for the company. Roth Capital reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Vascular Biogenics in a report on Thursday, June 9th. Chardan Capital reissued a “buy” rating on shares of Vascular Biogenics in a research note on Tuesday, June 7th. Finally, Piper Jaffray Cos. reissued a “buy” rating and set a $14.00 target price on shares of Vascular Biogenics in a research note on Tuesday, June 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $16.50.
The stock’s market cap is $93.28 million. The firm’s 50-day moving average is $4.11 and its 200-day moving average is $3.64.
Vascular Biogenics (NASDAQ:VBLT) last released its earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.21). Equities research analysts predict that Vascular Biogenics Ltd. will post ($0.82) earnings per share for the current fiscal year.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.